The content on this site is intended for healthcare professionals only
Prof Xavier Leleu speaks to ecancer about updated results from the phase III BENEFIT trial comparing isatuximab plus bortezomib, lenalidomide and dexamethasone (Isa-VRd) with isatuximab plus lenalidomide and dexamethasone (Isa-Rd) in transplant-ineligible newly diagnosed multiple myeloma.
He reports that at approximately four years of follow-up, progression-free survival remained numerically higher with Isa-VRd, although the difference between the treatment groups was not statistically significant.
Prof Leleu highlights a potentially greater benefit among patients with high-risk multiple myeloma, with a 48-month progression-free survival rate of 63.1% with Isa-VRd compared with 40.2% with Isa-Rd.
Long-term modelling also suggests that the progression-free survival benefit of Isa-VRd may become more apparent with longer follow-up, supporting its role as a standard-of-care option for transplant-ineligible patients aged 65–79 years.
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM
